230 filings
Page 2 of 12
6-K
fc9 rrqgfnwa79quecdn
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
tlt0fw3q
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
i3iwjt8a wte85vou9td
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
33w2 37doc
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
vc7pa1ysb
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
logvpx
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
tgldwgcn s9mkq
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
mqjrqilwvh pfsap
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
6tkrp88ve9d99bboll
18 Aug 23
Report of Foreign Private Issuer
4:01pm
6-K
gngxswi7
14 Aug 23
Supplemental Proxy Statement
5:29pm
6-K
zlvmww 2yq
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
dsr g6pakpuf2ww
9 Aug 23
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
7:30pm
6-K
gi3m6rjxv7x4dw3m
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
r5c lmrot
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
islp1kap
11 Jul 23
Report of Foreign Private Issuer
4:16pm
6-K
sbcvyohdh
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
r3uvj69
26 Jun 23
Report of Foreign Private Issuer
4:04pm
6-K
w0l9z7 lf
21 Jun 23
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
9:08am
6-K
l6t3zj43k
16 Jun 23
Report of Foreign Private Issuer
9:09am
6-K
vqea y9z81
12 Jun 23
SciSparc Grants an Exclusive License for the Sales of CannAmideā¢ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
7:02am